Gilead Sciences vs GSK
GILD and GSK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GILD and GSK compare
Gilead Sciences grew revenue faster over the last twelve months (5.5% versus 4.1% for GSK).
GSK keeps more of each dollar of sales as profit, with a net margin of 17.5% compared with −10.6% at Gilead Sciences.
Gilead Sciences pays a dividend yielding 1.9%; GSK does not pay one.
Gilead Sciences scores higher on the StockData Score (11 against 9 for GSK), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GILD | GSK |
|---|---|---|
| Size and price | ||
| Market cap | $212B | – |
| Share price | $170.68 | $49.51 |
| Change, 1 year | 44.0% | 7.8% |
| Change, 5 years | 157% | −7.1% |
| Beta (5Y) | 0.44 | 0.26 |
| Employees | 17K | 500K |
| StockData Score | ||
| Total score | 11 (better) | 9 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 3 | 4 (better) |
| Health score | 3 | 3 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/S | 6.9× | – |
| P/B | 17.9× | – |
| P/FCF | 16.4× | – |
| FCF yield | 6.1% | – |
| Fair value | $83.31 | – |
| Margin of safety | −105% | – |
| Growth | ||
| Revenue growth (TTM) | 5.5% (better) | 4.1% |
| Revenue growth, 5Y average | 3.6% | 6.0% (better) |
| Net income growth (TTM) | −151% | 122% (better) |
| EPS growth (TTM) | −154% | 123% (better) |
| EPS growth, 5Y average | 132% (better) | −0.54% |
| Profitability | ||
| Gross margin | 79.6% (better) | 72.4% |
| Operating margin | −8.2% | 24.3% (better) |
| Net margin | −10.6% | 17.5% (better) |
| FCF margin | 42.5% (better) | 19.6% |
| Return on equity | −20.6% | 38.0% (better) |
| Return on invested capital | −5.3% | 23.4% (better) |
| Financial health | ||
| Debt / equity | 2.22 | 1.08 (better) |
| Net debt / EBITDA | – | 1.40 |
| Interest coverage | −2.5× | 11.3× (better) |
| Current ratio | 1.27 (better) | 0.82 |
| Altman Z-score | 3.96 | – |
| Piotroski F-score | 8 | 9 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.9% | – |
| Payout ratio | – | 44.9% |
| Years of dividend growth | 11 | – |
| Dividend growth, 5Y average | 3.0% | – |
| Buyback yield | 0.54% | – |
| Shareholder yield | 2.4% | – |
| Ownership | ||
| Held by institutions | 89.9% | 8.0% |
| Held by insiders | 0.10% | 0.05% |
| Insider net buying, 12 months | −$83.5M | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 1.8% | – |
Go deeper
- GILD stock overview
- GILD income statement
- GILD valuation and score
- GSK stock overview
- GSK income statement
- GSK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.